Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat

The goal of this clinical trial is to assess the feasibility of pharmacokinetically boosting osimertinib using cobicistat in order to improve osimertinib exposure in individual patients with advanced NSCLC (Non-Small Cell Lung Cancer) with mutated EGFR (Epidermal Growth Factor Receptor). The main questions it aims to answer are: * Cohort 1: Does concurrent use of osimertinib and cobicistat allow for osimertinib weekly intake reductions? If so, how much can the intake be reduced while retaining clinically effective exposure? * Cohort 2: Does concurrent use of osimertinib and cobicistat allow f

Trial Details

NCT ID
NCT05748093
Phase
PHASE4
Sponsor
Maastricht University Medical Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Cobicistat
Locations (sample)
  • Maastricht, Limburg, Netherlands|50.84833,5.68889

Key Eligibility Criteria

  • In order to be eligible to participate in this cohort 1, a subject must meet all of the following criteria:
  • The patient is set to receive osimertinib 80 mg QD as part of their standard treatment plan
  • The patient has a World Health Organization (WHO) Performance Status (PS) of ≤2.
  • The patient is 18 years or older

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →